Cargando...
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Libertas Academica
2012
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3327515/ https://ncbi.nlm.nih.gov/pubmed/22518088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6460 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|